-

AM Best Affirms Credit Ratings of Arab War Risks Insurance Syndicate

LONDON--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating of B++ (Good) and the Long-Term Issuer Credit Rating of “bbb+” (Good) of Arab War Risks Insurance Syndicate (AWRIS) (Bahrain). The outlook of these Credit Ratings (ratings) is stable.

The ratings reflect AWRIS’ balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, limited business profile and appropriate enterprise risk management.

AWRIS’ balance sheet strength is underpinned by its risk-adjusted capitalisation, which is comfortably in excess of the threshold required for the strongest assessment, as measured by Best’s Capital Adequacy Ratio (BCAR). The syndicate’s balance sheet strength assessment benefits from a relatively conservative investment strategy, low net underwriting leverage and prudent reserving practices. AM Best considers AWRIS to have a very high dependence on retrocession coverage in order to provide capacity to members and manage potential volatility from large losses. Due to the company’s track record of robust underwriting profitability, combined with strong relationships with multiple reinsurance counterparties, the risk of non-renewal of the reinsurance programme is limited. Given the nature of AWRIS’ operations and membership structure as a syndicate of (re)insurance companies in the Middle East and North Africa (MENA) region, risks associated with the permanence of capital is a further offsetting factor.

AWRIS has a track record of strong operating performance, demonstrated by a five-year (2019-2023) weighted average combined ratio of 65.7% and a five-year return-on-equity ratio (ROE) of 6.0%. AWRIS’ underwriting performance has been supported by low loss ratios, demonstrated by a five-year weighted average loss ratio of 2.0%. The syndicate’s ROE metrics are considered supportive of the strong operating performance assessment given its high level of capitalisation.

AWRIS has an established position as a niche underwriter of marine war risks across the MENA region for its members. As a niche operator, AM Best views the syndicate’s concentration by line of business as an offsetting factor, albeit the syndicate is starting to expand its product offering with the support of reinsurance partners. There is limited dependence on any single member with regard to premium income, and the syndicate has seen some growth in members in recent years. Nevertheless, there remains a reliance on continued membership participation.

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2024 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Romeo Berti
Senior Financial Analyst
+44 20 7397 0267
romeo.berti@ambest.com

Jessica Botelho-Young, CA
Associate Director, Analytics
+44 20 7397 0310
jessica.botelho-young@ambest.com

Christopher Sharkey
Associate Director, Public Relations
+1 908 882 2310
christopher.sharkey@ambest.com

Al Slavin
Senior Public Relations Specialist
+1 908 882 2318
al.slavin@ambest.com

AM Best


Release Versions
Hashtags

Contacts

Romeo Berti
Senior Financial Analyst
+44 20 7397 0267
romeo.berti@ambest.com

Jessica Botelho-Young, CA
Associate Director, Analytics
+44 20 7397 0310
jessica.botelho-young@ambest.com

Christopher Sharkey
Associate Director, Public Relations
+1 908 882 2310
christopher.sharkey@ambest.com

Al Slavin
Senior Public Relations Specialist
+1 908 882 2318
al.slavin@ambest.com

Social Media Profiles
More News From AM Best

AM Best Assigns Credit Ratings to Charp Re, Ltd.

MEXICO CITY--(BUSINESS WIRE)--AM Best has assigned a Financial Strength Rating of B++ (Good) and a Long-Term Issuer Credit Rating (Long-Term ICR) of “bbb” (Good) to Charp Re, Ltd. (Charp Re) (Turks & Caicos Islands). The outlook assigned to these Credit Ratings (ratings) is stable. The ratings reflect Charp Re’s balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management (ER...

AM Best Revises Outlooks to Positive for FMH Insurance Group’s Members

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has revised the outlooks to positive from stable and affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Farmers Mutual Hail Insurance Company of Iowa and its reinsured affiliate, FMH Ag Risk Insurance Company. Both companies are domiciled in West Des Moines, IA and are collectively referred to as FMH Insurance Group (FMH).The Credit Ratings (ratings) reflect FMH’s overall balance sheet str...

Best’s Commentary: Health Insurers Evaluating Balance Between Pharmacy Costs and Long-Term Value of GLP-1 Therapies

OLDWICK, N.J.--(BUSINESS WIRE)--As pharmacy cost trends continue to rise and clinical evidence evolves, health insurers face a fundamental question on whether improvements in long-term morbidity and the potential for improved mortality outcomes ultimately justify significant investments in GLP-1 therapies, according to a new AM Best commentary. The Best’s Commentary, “GLP-1 Therapies: Evaluating the Balance Between Pharmacy Costs and Long-Term Value,” states that GLP-1 therapies have become one...
Back to Newsroom